TABLE 2.
Frequency of KIR genotypes, KIR genes, and HLA class I ligands in the control group and COVID-19 patients.
| Hospitalized COVID-19 patients | |||||
|---|---|---|---|---|---|
| All patients (A) n = 200 | Mild (M) n = 93 | Severe (S) n = 107 | Controls (C) n = 195 | Comparisons: p-value, OR (95% CI) | |
| KIR Genotypes | %F(N+) | %F (N+) | %F (N+) | %F (N+) | |
| AA genotypes | 30.0 (60) | 32.3 (30) | 28.0 (30) | 30.8 (60) | |
| Bx genotypes | 70.0 (140) | 67.7 (63) | 72.0 (77) | 69.2 (140) | |
| C4 cluster | 19.0 (38) | 18.3 (17) | 19.6 (21) | 25.7 (50) | |
| T4 cluster | 33.5 (67) | 28.0 (26) | 38.3 (41) | 27.2 (53) | SxC: 0.0001, 4.3 (2.6–7.1) |
| B haplotype-associated genes | |||||
| Centromeric genes | |||||
| 2DS2 | 52.5 (105) | 51.6 (48) | 53.3 (57) | 49.7 (97) | |
| 2DL2 | 49.5 (99) | 48.4 (45) | 50.5 (54) | 49.2 (96) | |
| 2DS3 | 26.0 (52) | 22.6 (21) | 29.0 (31) | 28.2 (55) | |
| 2DL5 | 53.5 (107) | 50.5 (47) | 56.1 (60) | 52.8 (103) | |
| Telomeric genes | |||||
| 3DS1 | 40.0 (80) | 36.6 (34) | 43.0 (46) | 39.5 (77) | |
| 2DS5 | 38.0 (76) | 31.2 (29) | 43.9 (47) | 35.9 (70) | |
| 2DS1 | 42.5 (85) | 36.6 (34) | 47.7 (51) | 37.4 (73) | |
| 3DS1 + 2DS5 + | 34.0 (68) | 28.0 (26) | 39.3 (42) | 30.3 (59) | |
| 3DS1 + 2DS1 + | 39.0 (78) | 35.5 (33) | 42.1 (45) | 32.3 (63) | |
| 2DS1 + 2DS5 + | 35.0 (70) | 28.0 (26) | 41.1 (44) | 30.8 (60) | SxM: 0.05, 1.8 (1–3.3) |
| 3DS1 + 2DS5 + 2DS1 + | 33.5 (67) | 28.0 (26) | 38.3 (41) | 27.2 (53) | SxC: 0.046, 1.7 (1.0–2.7) |
| A haplotype-associated genes | |||||
| 2DL1 | 94.5 (189) | 95.7 (89) | 93.5 (100) | 96.9 (189) | |
| 2DL3 | 93.0 (186) | 93.5 (87) | 92.5 (99) | 88.7 (173) | |
| 3DL1 | 93.0 (186) | 94.6 (88) | 91.6 (98) | 94.9 (185) | |
| 2DS4 | 92.0 (184) | 93.5 (87) | 90.7 (97) | 94.9 (185) | |
| Pseudogenes and Framework genes | |||||
| 2DP1 | 94.5 (189) | 95.7 (89) | 93.5 (100) | 98.0 (191) | |
| 3DP1 | 100.0 (200) | 100.0 (93) | 100.0 (107) | 100.0 (195) | |
| 2DL4 | 99.5 (199) | 100.0 (93) | 99.1 (106) | 100.0 (195) | |
| 3DL2 | 100.0 (200) | 100.0 (93) | 100.0 (107) | 100.0 (195) | |
| 3DL3 | 100.0 (200) | 100.0 (93) | 100.0 (107) | 100.0 (195) | |
| KIR-binding HLA class I ligands | |||||
| C1 | 86.0 (172) | 86.0 (80) | 86.0 (92) | 80.0 (156) | |
| C2 | 58.5 (117) | 64.5 (60) | 53.3 (57) | 58.5 (114) | |
| Bw4 | 48.0 (96) | 46.2 (43) | 49.5 (53) | 55.9 (109) | |
| Bw4 I80 | 34.5 (69) | 34.4 (32) | 34.6 (37) | 34.4 (67) | |
| Bw4 T80 | 22.0 (44) | 17.2 (16) | 26.2 (28) | 30.3 (59) | MxC: 0.019, 0.48 (0.3–0.89) |
| A3/11 | 25.0 (50) | 26.9 (25) | 23.4 (25) | 35.4 (69) | AxC: 0.025, 0.61 (0.39–0.94); SxC: 0.032, 0.56 (0.33–0.95) |
| A3 | 11.5 (23) | 14.0 (13) | 9.3 (10) | 26.2 (51) | AxC: 0.0003, 0.37 (0.21–0.63) |
| A11 | 15.0 (30) | 12.9 (12) | 16.8 (18) | 11.3 (22) | |
Frequency (%F) of each genotype is expressed as a percentage and defined as the number of individuals having the genotype (N+) divided by the number of individuals studied (n) in the study group;OR, Odds ratio; CI, Confidence interval; Comparisons: AxC, all patients vs. controls, MxC, mild vs. controls, SxC, severe vs. controls, SxM, sever vs. mild.
Values shows significant difference are shown in bold.